** Shares of Chinese biopharmaceutical products developer 3SBio Inc 1530.HK jump as much as 51.7% to HK$22, highest since June 2018
** Set for biggest one-day pct rise since listing in 2015; top pct gainer on Hang Seng Biotech Index .HSHKBIO and healthcare index .HSCIH, which are up 2.7% and 2.6%
** Pfizer FE.N has signed a $6 billion licensing agreement with 3SBio Inc for development, manufacturing and commercialization of a drug that could be used to treat certain types of cancer and tumors
** 3SBio and its subsidiaries will grant Pfizer a global license, excluding China, for the drug SSGJ-707, with an option for Pfizer to obtain commercialization rights in China
** Pfizer to also make a $100 million investment in 3SBio after transaction close, expected in Q3
** 3SBio's unit Sunshine Guojian Pharmaceutical 688336.SS jumps 20% to 39.37 yuan, highest since August 2020
** Hang Seng Index .HSI rises 1%
** YTD, 3SBio stock up 217.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.